The observations include aspects such as lack of appropriate test measures for lab controls along with some procedural issues too.
Shares of Sun Pharmaceutical fell over 5 percent on Friday morning on buzz of observations being issued by the US drug regulator for its Halol plant.
The stock touched an intraday high of Rs 658.00 and an intraday low of Rs 640.95.
According to reports on CNBC-TV18, the US Food and Drug Administration (FDA) issued six observations for its Halol unit in Gujarat.
The observations include aspects such as lack of appropriate test measures for lab controls along with some procedural issues too.
Further, the report quoted observations such as procedures designed to prevent objectionable microorganisms were not followed. It also said that written stability programme did not include sample size based on statistical data.
Cleaning and maintenance of equipment did not see any written procedures being followed as well.The stock has gained 13 percent in the past one month, while in the past three days, it has fallen a percent. At 09:34 hrs, the stock was quoting at Rs 648.05, down Rs 28.60, or 4.23 percent, on the BSE.
Best services for customers with full technical support make your Financial Trading more easy click here to subscribe us for free >>Nifty Future Tips and Ripples Advisory
No comments:
Post a Comment